Angiotensin II receptor blockers (ARB) block the action of angiotensin II, a hormone normally produced by the kidneys. By blocking the effect of angiotensin II, angiotensin II receptor blockers relax the blood vessels, which lowers blood pressure. This means that your heart does not need to work hard to push blood through the body.
The effectiveness of reducing blood pressure with drugs from this group depends on the initial activity of the renin-angiotensin system. Most strongly they act on patients with high activity of renin in blood plasma. You can check it by submitting a blood test. All angiotensin II receptor blockers have a long-lasting effect on lowering blood pressure, which lasts for 24 hours. This effect manifests itself after 2-4 weeks of therapy and is increased by the 6th-8th week of treatment. Most drugs cause a dose-dependent reduction in arterial pressure. It is important that they do not violate its normal circadian rhythm.
The available clinical observations suggest that with prolonged use of angiotensin receptor blockers (for two years or more), there is no getting used to their action. Cancellation of treatment does not lead to a “ricochet” increase in blood pressure. Blockers of angiotensin II receptors do not lower the blood pressure level if it is within the normal range. When compared with tablets of other classes, it is noted that the Sartans, having a similarly powerful effect on lowering blood pressure, cause fewer side effects and are better tolerated by patients.
Angiotensin receptor antagonists not only reduce blood pressure, but also improve kidney function in diabetic nephropathy, cause regression of left ventricular hypertrophy of the heart, and improve heart failure. In recent years, a debate has developed in the literature about the ability of these pills to increase the risk of developing fatal myocardial infarction. Several studies on the negative impact of Sartans on the incidence of myocardial infarction have not been done correctly. It is now believed that the ability of angiotensin II receptor blockers to increase the risk of developing fatal myocardial infarction is not proven.